

Special Issue

Gut Microbiota, Inflammatory Bowel Diseases, and Therapeutic Targets

Message from the Guest Editors

The intestinal microbiota and its microbiome have received special attention during the last two decades. It is a sensitive ecosystem, symbiotic with the human body, that offers multiple benefits to the development and function of the gastrointestinal tract and the intestinal immune system. Disruption of its composition, known as dysbiosis, has been associated with disorders of the digestive tract, but also with other organs and systems. There is extensive evidence implicating dysbiosis in the pathogenesis of chronic intestinal inflammation and inflammatory bowel diseases (IBDs). IBDs include Crohn's disease and ulcerative colitis, two chronic idiopathic inflammatory conditions without known etiopathology and therapy. Since altered microbiota has been proposed as a possible cause of IBD, manipulation of the microbiota and restoring dysbiosis through the diet, probiotics, or fecal transplantation are under investigation as therapeutic strategies of IBD. This Special Issue aims to present the latest findings on the role of gut microbiota in IBD, covering a broad field from the study of pathogenetic mechanisms to therapeutic interventions.

Guest Editors

Prof. Dr. George Kolios

Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece

Dr. Eirini Filidou

Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece

Deadline for manuscript submissions

closed (15 May 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



mdpi.com/si/50528

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)